L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance

NCT ID: NCT07220447

Last Updated: 2026-02-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-04-01
• Study Completion Date: 2027-07-09

Brief Summary

This clinical trial tests the feasibility, best dose, and effectiveness of L-theanine for supporting relaxation and mood among cancer patients in surveillance. L-theanine is a substance found in the leaves of green tea with potential to enhance mental health and well-being. It works by increasing certain chemicals within the body that have been associated with stress reduction, mood stabilization, and improved cognitive performance.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the feasibility of L-theanine use among cancer patients in surveillance based on adherence.

II. To determine the relationship of L-theanine on relaxation and supporting mood among cancer patients in surveillance with a dose of 200mg once daily versus (vs) twice daily, as measured by Visual Analog Scale-Relaxation (VAS-R).

SECONDARY OBJECTIVES:

I. To observe the relationship of L-theanine in reducing anxiety among cancer patients in surveillance, as measured by Visual Analog Scale-Anxiety (VAS-A).

II. To observe the relationship of L-theanine on mood states as measured by Short Form of the Profile of Mood States (POMS-SF).

EXPLORATORY OBJECTIVES:

I. To determine the feasibility of L-theanine use among cancer patients in surveillance based on recruitment.

II. To observe the relationship of L-theanine in supporting sleep among cancer patients in surveillance as measured by the Pittsburgh Sleep Quality Index (PSQI).

III. To describe the side effects of L-theanine supplementation. IV. To observe the relationship between L-theanine on symptom burden among cancer patients in surveillance as measured by Edmonton Symptom Assessment Scale (ESAS).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive L-theanine orally (PO) once daily (QD) for 6 weeks in the absence of unacceptable toxicity.

ARM II: Patients receive L-theanine PO twice daily (BID) for 6 weeks in the absence of unacceptable toxicity.

After completion of study intervention, patients are followed up at 14 days.

Conditions

Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Arm I (L-theanine QD)

Patients receive L-theanine PO QD for 6 weeks in the absence of unacceptable toxicity.

Group Type: EXPERIMENTAL

Survey Administration

Intervention Type: OTHER

Ancillary studies

Theanine

Intervention Type: DRUG

Given L-theanine PO

Arm II (L-theanine BID)

Patients receive L-theanine PO BID for 6 weeks in the absence of unacceptable toxicity.

Group Type: EXPERIMENTAL

Survey Administration

Intervention Type: OTHER

Ancillary studies

Theanine

Intervention Type: DRUG

Given L-theanine PO

Interventions

Survey Administration

Ancillary studies

Intervention Type: OTHER

Theanine

Given L-theanine PO

Intervention Type: DRUG

Other Intervention Names

L-theanine; N-Ethyl-L-Glutamine; Suntheanine; Theanin

Eligibility Criteria

Inclusion Criteria

• Documented informed consent of the participant and/or legally authorized representative.

• Assent, when appropriate, will be obtained per institutional guidelines
• Willingness to comply with all study interventions including the use of L-theanine and follow-up assessments
• Age: ≥ 18 years
• Ability to read and understand English or Spanish for questionnaires
• Patients must be a cancer patient who has completed treatment and has been in surveillance for at least 6 months
• Participants must not have used any herbs or supplements in the past 30 days
• Participants must report an anxiety score of > 3 on Visual Analog Scale - Anxiety
• Participants must not have had any changes to their psychiatric medications within the past 60 days
• Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
• Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 month after the last dose of protocol therapy.

• Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria

• Concurrent use of other alternative medicines, including herbal agents and high-dose vitamins and minerals, unless taken to correct a documented vitamin or mineral insufficiency
• Chemotherapy, radiation therapy, biological therapy, immunotherapy, or any other systemic treatment excluding hormonal therapy (must be on a stable dose of hormonal therapy for at least 60 days)
• Any patients taking bortezomib, as L-theanine can decrease effectiveness
• Any patients currently enrolled in other clinical trials that might interfere with the results of this study
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
• Any patients with an ongoing active/unstable psychiatric condition, depressive/bi-polar related disorders, anxiety, psychosis disorders, or substance use that may interfere with the ability to participate in the study as outlined in the study procedures section of the protocol
• Any patients with chronically unstable blood pressure or chronic low blood pressure
• Diagnosis of Gilbert's disease
• Females only: Pregnant or breastfeeding
• Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

City of Hope Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Erica Veguilla

Role: PRINCIPAL_INVESTIGATOR

City of Hope Medical Center

Locations

City of Hope Medical Center

Duarte, California, United States

Site Status: RECRUITING

City of Hope Seacliff

Huntington Beach, California, United States

Site Status: NOT_YET_RECRUITING

City of Hope at Irvine Lennar

Irvine, California, United States

Site Status: NOT_YET_RECRUITING

City of Hope at Irvine Sand Canyon

Irvine, California, United States

Site Status: NOT_YET_RECRUITING

Countries

United States

Facility Contacts

Erica Veguilla

Role: primary

eveguilla@coh.org

949-671-4673

Erica Veguilla

Role: primary

eveguilla@coh.org

949-671-4673

Erica Veguilla

Role: primary

eveguilla@coh.org

949-671-4673

Erica Veguilla

Role: primary

eveguilla@coh.org

949-671-4673

Other Identifiers

NCI-2025-05686

Identifier Type: REGISTRY

Identifier Source: secondary_id

24886

Identifier Type: OTHER

Identifier Source: secondary_id

P30CA033572

Identifier Type: NIH

Identifier Source: secondary_id

View Link

24886

Identifier Type: -

Identifier Source: org_study_id